MX2017010793A - Terapeuticos de anticuerpo que ligan cd137. - Google Patents
Terapeuticos de anticuerpo que ligan cd137.Info
- Publication number
- MX2017010793A MX2017010793A MX2017010793A MX2017010793A MX2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- derivatives
- polypeptides
- methods
- fragments
- Prior art date
Links
- 229940124691 antibody therapeutics Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000027317 positive regulation of immune response Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119211P | 2015-02-22 | 2015-02-22 | |
| PCT/US2016/018897 WO2016134358A1 (en) | 2015-02-22 | 2016-02-22 | Antibody therapeutics that bind cd137 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010793A true MX2017010793A (es) | 2018-07-06 |
Family
ID=56690285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010793A MX2017010793A (es) | 2015-02-22 | 2016-02-22 | Terapeuticos de anticuerpo que ligan cd137. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10233251B2 (OSRAM) |
| EP (1) | EP3258959A4 (OSRAM) |
| JP (1) | JP2018508509A (OSRAM) |
| KR (1) | KR20180016972A (OSRAM) |
| CN (1) | CN107921104A (OSRAM) |
| AR (1) | AR105313A1 (OSRAM) |
| AU (1) | AU2016219772A1 (OSRAM) |
| CA (1) | CA2977257A1 (OSRAM) |
| IL (1) | IL254088A0 (OSRAM) |
| MX (1) | MX2017010793A (OSRAM) |
| TW (1) | TW201632559A (OSRAM) |
| WO (1) | WO2016134358A1 (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| AU2016219772A1 (en) * | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
| CN107709367A (zh) * | 2015-05-21 | 2018-02-16 | 鳄鱼生物科学公司 | 新型多肽 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| EP3544628A4 (en) | 2016-11-23 | 2020-11-18 | Immunoah Therapeutics, Inc. | 4-1BB BINDING PROTEINS AND THEIR USES |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| CA3059366A1 (en) * | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| IL322943A (en) | 2017-07-11 | 2025-10-01 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and their use |
| JOP20200016B1 (ar) * | 2017-08-01 | 2022-10-30 | Lilly Co Eli | أجسام مضادة لـ cd137 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| KR102758346B1 (ko) * | 2017-08-04 | 2025-01-24 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| US12202911B2 (en) * | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| TWI701259B (zh) | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019104716A1 (en) * | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2021514953A (ja) * | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| MA52075A (fr) | 2018-03-23 | 2021-01-27 | Lilly Co Eli | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-l1 |
| SG11202009791VA (en) * | 2018-04-09 | 2020-11-27 | Origincell Therapeutics Co Ltd | Anti-pd-l1 antibody and use thereof |
| TW202003580A (zh) | 2018-05-21 | 2020-01-16 | 美商坎伯斯治療有限責任公司 | 用於增強nk細胞對標靶細胞之殺死之組合物及方法 |
| EA202190138A1 (ru) * | 2018-06-29 | 2021-05-27 | ЭЛЕКТОР ЭлЭлСи | Анти-sirp-бета1 антитела и способы их использования |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| AU2019301204B2 (en) | 2018-07-12 | 2025-10-23 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| JP7090204B2 (ja) * | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| EP3850012A4 (en) | 2018-09-12 | 2022-06-15 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-TNFRSF9 ANTIBODIES AND THEIR USES |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| MY206649A (en) * | 2018-11-30 | 2024-12-30 | I Mab Biopharma Us Ltd | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| WO2020142624A1 (en) * | 2019-01-02 | 2020-07-09 | Qlsf Biotherapeutics Inc. | Cd137 agonist antibodies and uses thereof |
| JP7695698B2 (ja) * | 2019-01-14 | 2025-06-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞内部移行をモジュレートするための組成物および方法 |
| SG11202109163YA (en) * | 2019-02-26 | 2021-09-29 | Sorrento Therapeutics Inc | Antigen binding proteins that bind bcma |
| AU2020263959A1 (en) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| WO2020247290A1 (en) * | 2019-06-04 | 2020-12-10 | Academia Sinica | Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors |
| AU2020308463A1 (en) * | 2019-06-26 | 2022-02-17 | Ap Biosciences, Inc. | Antibodies for T-cell activation |
| EP4041772A4 (en) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co., Ltd. | 4-1BB-BINDING ANTIBODIES AND USES THEREOF |
| US20230068663A1 (en) * | 2020-02-05 | 2023-03-02 | The Board Of Regents Of The University Of Texas System | Novel lilrb2 antibodies and uses thereof |
| CN115605228A (zh) * | 2020-04-17 | 2023-01-13 | 苏州丁孚靶点生物技术有限公司（Cn） | 一种特异性结合cd137的制剂及其用途 |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| CN116194124A (zh) * | 2020-07-31 | 2023-05-30 | 中外制药株式会社 | 包含表达嵌合受体的细胞的药物组合物 |
| CN116199778B (zh) * | 2021-12-01 | 2025-06-03 | 上海君实生物医药科技股份有限公司 | 抗4-1bb抗体及其用途 |
| CN115975032B (zh) * | 2022-12-19 | 2024-06-07 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
| WO2025049858A1 (en) * | 2023-09-01 | 2025-03-06 | Amgen Inc. | Molecules for treatment of cancer |
| WO2025189194A1 (en) * | 2024-03-08 | 2025-09-12 | Dana-Farber Cancer Institute, Inc. | Antibodies against vegf and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27087A1 (es) * | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| DE60232895D1 (de) | 2001-10-09 | 2009-08-20 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
| US20030223989A1 (en) * | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2006088447A1 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2016219772A1 (en) | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
| JP2018510151A (ja) * | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Ｔｉｍ３に結合する抗体医薬 |
| TW202035451A (zh) * | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| EP3864049A1 (en) * | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
-
2016
- 2016-02-22 AU AU2016219772A patent/AU2016219772A1/en not_active Abandoned
- 2016-02-22 KR KR1020177026952A patent/KR20180016972A/ko not_active Withdrawn
- 2016-02-22 EP EP16753215.9A patent/EP3258959A4/en not_active Withdrawn
- 2016-02-22 US US15/049,718 patent/US10233251B2/en active Active
- 2016-02-22 US US15/050,215 patent/US10259881B2/en active Active
- 2016-02-22 WO PCT/US2016/018897 patent/WO2016134358A1/en not_active Ceased
- 2016-02-22 TW TW105105159A patent/TW201632559A/zh unknown
- 2016-02-22 MX MX2017010793A patent/MX2017010793A/es unknown
- 2016-02-22 CN CN201680022446.1A patent/CN107921104A/zh active Pending
- 2016-02-22 CA CA2977257A patent/CA2977257A1/en not_active Abandoned
- 2016-02-22 JP JP2017544293A patent/JP2018508509A/ja not_active Withdrawn
- 2016-02-23 AR ARP160100459A patent/AR105313A1/es unknown
-
2017
- 2017-08-21 IL IL254088A patent/IL254088A0/en unknown
-
2019
- 2019-02-08 US US16/270,761 patent/US11180568B2/en not_active Expired - Fee Related
-
2021
- 2021-10-12 US US17/499,127 patent/US20220025064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3258959A4 (en) | 2018-10-17 |
| WO2016134358A1 (en) | 2016-08-25 |
| CN107921104A (zh) | 2018-04-17 |
| KR20180016972A (ko) | 2018-02-20 |
| US10259881B2 (en) | 2019-04-16 |
| IL254088A0 (en) | 2017-10-31 |
| US11180568B2 (en) | 2021-11-23 |
| US10233251B2 (en) | 2019-03-19 |
| US20160244528A1 (en) | 2016-08-25 |
| TW201632559A (zh) | 2016-09-16 |
| EP3258959A1 (en) | 2017-12-27 |
| JP2018508509A (ja) | 2018-03-29 |
| AR105313A1 (es) | 2017-09-27 |
| US20220025064A1 (en) | 2022-01-27 |
| AU2016219772A1 (en) | 2017-09-21 |
| CA2977257A1 (en) | 2016-08-25 |
| US20170226215A1 (en) | 2017-08-10 |
| US20190161554A1 (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010793A (es) | Terapeuticos de anticuerpo que ligan cd137. | |
| MX2021007947A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| WO2016144803A3 (en) | Antibody therapeutics that bind tim3 | |
| WO2017015560A3 (en) | Antibody therapeutics that bind lag3 | |
| WO2016164669A3 (en) | Antibody therapeutics that bind cd38 | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| WO2016141328A3 (en) | Antibody therapeutics that bind cd47 | |
| MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| CR20210325A (es) | Anticuerpos que se unen a cd3 | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
| MY200335A (en) | Bispecific binding proteins and uses thereof | |
| PH12017501347A1 (en) | Agonistic icos binding proteins | |
| WO2016164657A3 (en) | Antibody therapeutics that bind cd123 | |
| EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| NZ749578A (en) | Anti-met antibodies and uses thereof | |
| TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies | |
| MA39847A (fr) | Protéines de liaison à l'antigène se liant à wisp1 | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
| PH12022550460A1 (en) | Anti-cd96 antibodies and methods of use thereof |